Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34586105/

Diffuse large B-cell lymphoma (DLBCL) is a common lymphoproliferative and invasive disease. The current first-line regimen for the treatment of DLBCL is R-CHOP, which is the combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. R-CHOP has significantly improved the out ...